Showing 1551-1560 of 3038 results for "".
- Last Patient, Last Visit Completed in RegeneRx Phase 3 Dry Eye Clinical Trialhttps://modernod.com/news/last-patient-last-visit-completed-in-regenerx-phase-3-dry-eye-clinical-trial/2478508/RegeneRx Biopharmaceuticals announced that the final patient in its 700 subject, ARISE-3 phase 3 clinical trial for dry eye syndrome has completed treatment and follow-up. ARISE-3 is designed to assess the safety and efficacy of 0.1% RGN-259 eye drops compared to placebo after 2 weeks of
- Oyster Point Pharma Announces Tyrvaya Nasal Spray Now Covered by Express Scriptshttps://modernod.com/news/oyster-point-pharma-announces-tyrvaya-nasal-spray-now-covered-by-express-scripts/2480656/Oyster Point Pharma announced Tyrvaya Nasal Spray’s placement on the Express Scripts National Preferred, Basic, and High Performance Formularies, which collectively covers an estimated 26 million people, effective February 19, 2022. Tyrvaya is the first and only na
- Vision Expo East Cancelled Due to Coronavirus; Will Consolidate With Vision Expo West in Las Vegashttps://modernod.com/news/vision-expo-east-cancelled-due-to-coronavirus-will-consolidate-with-vision-expo-west-in-las-vegas/2477359/The organizers of Vision Expo announced that they are cancelling the scheduled Vision Expo East meeting scheduled to take place in New York, March 26-29, and consolidate that meeting with Vision Expo West in Las Vegas, Sept. 23-26. The decision was made due to concerns over the spread of the coro
- Novartis: New Analysis of Phase 3 Brolucizumab Data Reinforces Superior Reduction of Retinal Fluidhttps://modernod.com/news/novartis-new-analysis-of-phase-3-brolucizumab-data-reinforces-superior-reduction-of-retinal-fluid/2479846/Novartis announced a new data analysis showing that retinal fluid was detected less often in patients treated with brolucizumab (RTH258) 6 mg versus aflibercept over four visits between weeks 36 to 48[1]. Retinal fluid is a key marker of disease activity in neovascular age-related macular degener
- First Patient Treated in Multicenter Trial Examining Allotex TransForm Allogenic Refractive Lenticules for Treatment of Presbyopiahttps://modernod.com/news/first-patient-treated-in-multicenter-trial-examining-allotex-transform-allogenic-refractive-lenticules-for-treatment-of-presbyopia/2479889/Start-up ophthalmic device company Allotex announced the commencement of a European multicenter trial for its investigational TransForm allogenic refractive lenticules for the treatment of presbyopia. The treatment was performed on Thursday by Arthur Cummings, MB ChB, FCS(SA), MMed(Ophth)
- Novartis Acquires Arctos Medical, Expanding Optogenetics Portfoliohttps://modernod.com/news/novartis-acquires-arctos-medical-expanding-optogenetics-portfolio-to-bring-gene-therapies-to-patients-with-severe-vision-loss/2480291/Novartis announced that it has acquired Arctos Medical, adding a preclinical optogenetics-based AAV gene therapy program and Arctos’ proprietary technology to its ophthalmology portfolio. Financial terms of the deal were not disclosed. “Optogenetics is emergi
- J&J Vision Presents Data Validating Improved Surgical Outcomes and Surgeon Satisfaction at ASCRShttps://modernod.com/news/johnson-johnson-vision-presents-data-validating-improved-surgical-outcomes-and-surgeon-satisfaction-across-cataract-and-refractive-portfolio-at-ascrs/2480787/Johnson & Johnson Vision will present and/or support 46 company-sponsored and investigator-led studies evaluating innovations and outcomes across its surgical portfolio at the 2022 American Society of Cataract and Refractive Surgery (ASCRS) annual meeting in Washington, DC, April 22-26.
- Bausch + Lomb Introduces Pinnacle 360 25-Gauge Scleral Fixation Forcepshttps://modernod.com/news/bausch-lomb-introduces-pinnacle-360-25-gauge-scleral-fixation-forceps/2478053/Bausch + Lomb announced the introduction of the new Pinnacle 360 25-gauge Scleral Fixation Forceps. Bausch + Lomb will feature this innovation, as well as others in the company’s retina portfolio, during the virtual American Society of Retinal Specialists (ASRS) annual meeting, July 24-26, 2020.<
- Working With BARDA and FDA on COVID-19 Countermeasureshttps://modernod.com/news/covid-19-working-with-barda-and-fda-on-covid-19-countermeasures/2477443/How can biotech and pharmaceutical companies work with the government in developing and supplying effective diagnostics, treatments and vaccines for COVID-19? What should these companies know? Join Arnold & Porter on Thursday, March 26 from 12–2 pm Eastern Time for an introduction to c
- Updated Cataract PPP Raises Questions About Same-Day Bilateral Cataract Surgery and Office-based Cataract Surgeryhttps://modernod.com/news/updated-cataract-ppp-raises-questions-about-same-day-bilateral-cataract-surgery-and-office-based-cataract-surgery/2480467/The American Academy of Ophthalmology recognizes that immediate sequential bilateral cataract surgery (ISBCS) has the potential for some positive implications for patients. These include reduced out-of-pocket expense and fewer total visits to health care facilities. ISBCS has been adopted to a gr